NEW YORK (GenomeWeb News) – Genzyme Genetics has sublicensed rights for diagnostic testing of epidermal growth factor receptor mutations in non-small cell lung cancer to Manchester, UK-based DxS, the firms announced today.
 
The license grants DxS worldwide rights, except for North America and Hong Kong, to commercialize diagnostic and research products that detect mutations in the kinase domain of the EGFR gene.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.